


JAK2 Mutation (V617F) Analysis

Order Name: **JAK2 MUTAT**
Test Number: 9100185
Revision Date: 10/01/2022

TEST NAME	METHODOLOGY	LOINC CODE
JAK2 Mutation (V617F) Analysis	Qualitative PCR	

SPECIMEN REQUIREMENTS				
Specimen	Specimen Volume (min)	Specimen Type	Specimen Container	Transport Environment
Preferred	4mL (1mL)	Whole Blood	EDTA (Lavender Top)	Room Temperature
Instructions	<p>Do Not use EDTA that has been sampled by an instrument or shared with any other testing.</p> <p>4mL(1mL) Peripheral Whole Blood in EDTA Lavender top tube. Please keep specimens at room temperature or refrigerated. Do Not Centrifuge. Stability is 8 days room temperature and refrigerated.</p>			

GENERAL INFORMATION	
Testing Schedule	Dayshift- Friday
Expected TAT	5-6 Days
Clinical Use	Myeloproliferative disorders (MPDs) are clonal hematopoietic stem cell malignancies characterized by excessive production of blood cells by hematopoietic precursors. In addition to thrombotic and hemorrhagic complications, leukemic transformation can occur. The main members of MPD are Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Idiopathic Myelofibrosis (MF). The molecular pathogenesis of most MPDs is unknown. This V617F mutation leads to constitutive tyrosine phosphorylation activity that promotes cytokine activity and induces erythrocytosis. The V617F mutation in JAK2 is a dominant gain-of function mutation that contributes to the expansion of the myeloproliferative disorder clone.
Notes	
CPT Code(s)	81270
Service Provided By	 labcorp Oklahoma, Inc.